{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-18-011",
    "source_story_id": "tmp-story-optar-first-in-class-targets",
    "edition_id": "mp-2026-07-18-morning-0009",
    "edition_url": "https://themachinepress.com/edition/2026-07-18",
    "position": 11,
    "story_type": "dispatch",
    "section": "frontier-models",
    "editorial_classification": "editorial",
    "headline": "The Target Finder Looks Where No Drug Has Looked",
    "slug": "the-target-finder-looks-where-no-drug-has-looked",
    "dek": "OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.",
    "summary": "OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.",
    "body_text": "OPTAR excludes proteins already tied to a disease or existing drugs, scores indirect disease relevance through interaction networks, and checks AlphaFold structures for candidate pockets. In liver-cancer data it prioritized three proteins whose knockdown reduced cell viability and migration. Those cell experiments validate targets for further study, not medicines or patient benefit.",
    "why_it_matters": "OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.",
    "limitations": [
      "Those cell experiments validate targets for further study, not medicines or patient benefit."
    ],
    "importance": 8,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-18-011/the-target-finder-looks-where-no-drug-has-looked",
    "json_url": "https://themachinepress.com/story/mp-2026-07-18-011.json",
    "first_published_at": "2026-07-18T09:00:00.000-04:00",
    "modified_at": "2026-07-18T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-18-011-001",
        "text": "OPTAR filters omics candidates for novelty, disease-network relevance, and structural pockets before laboratory testing.",
        "source_ids": [
          "source-2026-07-18-011"
        ],
        "qualification": "Those cell experiments validate targets for further study, not medicines or patient benefit."
      }
    ],
    "source_ids": [
      "source-2026-07-18-011"
    ],
    "tags": [
      "drug discovery",
      "omics",
      "AlphaFold"
    ],
    "image_url": "https://themachinepress.com/issues/2026-07-18/optar-file-image.webp",
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-18-011",
      "title": "CAS via Newswise: OPTAR first-in-class targets",
      "publisher": "Chinese Academy of Sciences via Newswise",
      "url": "https://www.newswise.com/articles/optar-opens-a-new-route-to-first-in-class-drug-targets",
      "canonical_url": "https://www.newswise.com/articles/optar-opens-a-new-route-to-first-in-class-drug-targets",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": "2026-07-17T21:40:00.000-04:00",
      "accessed_at": "2026-07-18T08:25:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-18-011-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "The Target Finder Looks Where No Drug Has Looked",
    "publisher": "The Machine Press",
    "published_at": "2026-07-18T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-18-011/the-target-finder-looks-where-no-drug-has-looked"
  }
}